These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 23899496)
21. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Zheng W; Zhu XM; Zhang QE; Yang XH; Cai DB; Li L; Li XB; Ng CH; Ungvari GS; Ning YP; Xiang YT Schizophr Res; 2019 Apr; 206():13-20. PubMed ID: 30573406 [TBL] [Abstract][Full Text] [Related]
22. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. Zheng W; Wang S; Ungvari GS; Ng CH; Yang XH; Gu YH; Li M; Xiang YQ; Xiang YT J Clin Psychopharmacol; 2017 Jun; 37(3):341-346. PubMed ID: 28383359 [TBL] [Abstract][Full Text] [Related]
23. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576 [TBL] [Abstract][Full Text] [Related]
24. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. Solmi M; Veronese N; Thapa N; Facchini S; Stubbs B; Fornaro M; Carvalho AF; Correll CU CNS Spectr; 2017 Oct; 22(5):415-426. PubMed ID: 28181901 [TBL] [Abstract][Full Text] [Related]
25. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Zheng W; Li XH; Yang XH; Cai DB; Ungvari GS; Ng CH; Wang SB; Wang YY; Ning YP; Xiang YT Psychol Med; 2018 Jan; 48(1):72-81. PubMed ID: 28528597 [TBL] [Abstract][Full Text] [Related]
26. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Leucht S; Leucht C; Huhn M; Chaimani A; Mavridis D; Helfer B; Samara M; Rabaioli M; Bächer S; Cipriani A; Geddes JR; Salanti G; Davis JM Am J Psychiatry; 2017 Oct; 174(10):927-942. PubMed ID: 28541090 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials. Kishi T; Iwata N Pharmacopsychiatry; 2015 Jan; 48(1):30-6. PubMed ID: 25321187 [TBL] [Abstract][Full Text] [Related]
28. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Kishi T; Meltzer HY; Iwata N Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924 [TBL] [Abstract][Full Text] [Related]
29. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Poyurovsky M; Fuchs C; Pashinian A; Levi A; Faragian S; Maayan R; Gil-Ad I Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385 [TBL] [Abstract][Full Text] [Related]
30. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. Andrade C; Kisely S; Monteiro I; Rao S J Psychiatr Res; 2015 Jan; 60():14-21. PubMed ID: 25306261 [TBL] [Abstract][Full Text] [Related]
31. Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Zhu XM; Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Wang XP; Kulkarni J; Grigg J; Ning YP; Xiang YT Schizophr Res; 2018 Jul; 197():288-293. PubMed ID: 29395611 [TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Kishi T; Iwata N Int J Neuropsychopharmacol; 2014 Feb; 17(2):343-54. PubMed ID: 23823741 [TBL] [Abstract][Full Text] [Related]
33. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482 [TBL] [Abstract][Full Text] [Related]
34. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Hirota T; Kishi T Schizophr Res; 2013 Sep; 149(1-3):88-95. PubMed ID: 23870805 [TBL] [Abstract][Full Text] [Related]
35. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Vayısoğlu S; Karahan S; Anıl Yağcıoğlu AE Turk Psikiyatri Derg; 2019; 30(4):253-259. PubMed ID: 32594486 [TBL] [Abstract][Full Text] [Related]
36. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. Kishi T; Kafantaris V; Sunday S; Sheridan EM; Correll CU J Clin Psychiatry; 2012 Jun; 73(6):e757-66. PubMed ID: 22795216 [TBL] [Abstract][Full Text] [Related]
37. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R; J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184 [TBL] [Abstract][Full Text] [Related]
38. Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis. Vernon JA; Grudnikoff E; Seidman AJ; Frazier TW; Vemulapalli MS; Pareek P; Goldberg TE; Kane JM; Correll CU Schizophr Res; 2014 Nov; 159(2-3):385-94. PubMed ID: 25240772 [TBL] [Abstract][Full Text] [Related]
39. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. Kishi T; Matsuda Y; Nakamura H; Iwata N J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856 [TBL] [Abstract][Full Text] [Related]
40. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]